Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 13 Sept 2026Clinical review pending
Saved on this device
!
Flash pulmonary oedema with bilateral atherosclerotic RAS
Abrupt pulmonary oedema with acute fluid retention and kidney injury can be driven by bilateral haemodynamically important renal artery disease.
Action: Stabilise airway, breathing, blood pressure, congestion and renal function, stop nephrotoxins, obtain urgent renal vascular imaging and specialist input; ESVS 2025 advises considering stenting when bilateral atherosclerotic stenosis exceeds 50% in this phenotype.
Synopsis
Diagnose clinically important renal artery stenosis, use medical treatment safely, and reserve revascularisation for current high-risk phenotypes and thresholds.
Suspect RAS in resistant or abrupt-onset hypertension, unexplained renal decline, asymmetric kidneys, recurrent flash pulmonary oedema, diffuse atherosclerosis or deterioration after renin–angiotensin blockade; many anatomical stenoses are incidental.
Use renal artery duplex first. If it is inconclusive, use CTA or MRA for diagnosis and planning; ESVS recommends cross-sectional angiography over diagnostic catheter angiography.
Do not stent any RAS degree when blood pressure and renal function are controlled. Consider selected atherosclerotic stenting only for resistant hypertension on at least three drugs plus >70% stenosis, bilateral >50% disease with flash pulmonary oedema from acute fluid retention/AKI, or >70% disease with severe renal decline and preserved kidney viability.
Key red flags
Recurrent flash pulmonary oedema, rapidly accumulating fluid or otherwise unexplained acute kidney injury with bilateral disease requires urgent vascular and renal review.
A marked creatinine rise, oliguria, hyperkalaemia or hypotension after starting an ACE inhibitor or ARB suggests dependence on angiotensin-mediated efferent tone; stop and reassess urgently.
Resistant hypertension means blood pressure remains uncontrolled despite three or more appropriately chosen antihypertensive drugs; with atherosclerotic RAS >70%, this is a selected stenting indication rather than a reason to stent lesser incidental disease.
A small kidney, thinned cortex, heavy proteinuria or high renal resistance index suggests irreversible parenchymal loss and a low chance that revascularisation will restore function.
Investigation priorities
01
Renal artery duplex ultrasoundFirst stepFirst line
First-line imaging to assess ostial flow velocities, renal-aortic ratio, intrarenal waveforms, renal size and resistance indices.
Management branches
Worked controlled caseIncidental severe stenosis with stable control
CTA obtained for another reason shows 80% unilateral ostial RAS, but blood pressure is controlled and renal function stable.
Confirm the clinical history, kidney function, potassium, urine ACR and vascular risk; do not infer causality from the percentage alone.
Continue optimal medical therapy and surveillance: ESVS says angioplasty with or without stenting is not indicated at any stenosis degree when blood pressure and renal function are controlled.
Preferred stable medical pathwayUnilateral RAS with hypertension
Haemodynamically relevant unilateral stenosis is associated with hypertension but no high-risk revascularisation phenotype.
Key medicines
Ramipril 2.5 mg tabletsFor hypertension, start 2.5 mg orally once daily; consider 1.25 mg once daily with strongly activated RAAS, old/frail status, or creatinine clearance 10–30 mL/min. Double at 2–4-week intervals if tolerated, to a product maximum 10 mg/day when CrCl ≥60 and 5 mg/day when CrCl 10–60; haemodialysis patients start 1.25 mg after dialysis, maximum 5 mg/day.Check renal function and potassium before and soon after initiation/titration. Stop and reassess with major renal decline, hyperkalaemia, hypotension or angioedema. The product SmPC contraindicates significant bilateral RAS or RAS in a single functioning kidney, despite ESVS allowing carefully monitored class use in selected patients. Stop immediately if pregnancy occurs; contraindicated in second/third trimesters and avoid planned pregnancy.
Atorvastatin 10 mg film-coated tabletsUsual starting dose 10 mg orally once daily, taken any time with or without food; individualise to LDL response at intervals of at least four weeks, maximum 80 mg once daily. Continue long term for atherosclerotic risk reduction while tolerated.No renal dose adjustment is required. Check liver tests before treatment and if symptoms occur; active liver disease or persistent transaminases >3 times ULN contraindicate use. Stop for clinically important myopathy/rhabdomyolysis and review CYP3A4 interactions. Contraindicated in pregnancy, breastfeeding and women of child-bearing potential without contraception.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.